Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP

Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp.

KTTA

0.00
  • Coastlands Capital LP filed Form 3 disclosing 10% ownership in Pasithea Therapeutics (KTTA) tied to event date April 9, 2026.
  • Filing shows indirect beneficial ownership of 3,735,035 shares of common stock.
  • Coastlands also reported indirect ownership of pre-funded warrants exercisable for 11,233,334 shares at an exercise price of USD 0.001.
  • Pre-funded warrants have no expiration date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-045080), on April 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.